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Abstract
Background: Loss of the tumor suppressor phosphatase and tensin homolog (PTEN)
occurs frequently in prostate cancers. Preclinical evidence suggests that activation of
PI3K/AKT signaling through loss of PTEN can result in resistance to hormonal treatment
in prostate cancer.
Objective: To explore the antitumor activity of abiraterone acetate (abiraterone) in
castration-resistant prostate cancer (CRPC) patients with and without loss of PTEN
protein expression.
Design, setting, and participants: We retrospectively identiﬁed patients who had re-
ceived abiraterone and had hormone-sensitive prostate cancer (HSPC) and/or CRPC
tissue available for PTEN immunohistochemical analysis.
Outcome measurements and statistical analysis: The primary end point was overall
survival from initiation of abiraterone treatment. Relationship with outcome was ana-
lyzed using multivariate Cox regression and log-rank analyses.
Results and limitations: A total of 144 patients were identiﬁed who had received
abiraterone post-docetaxel and had available tumor tissue. Overall, loss of PTEN expres-
sion was observed in 40% of patients. Matched HSPC and CRPC tumor biopsies were
available for 41 patients. PTEN status in CRPC correlated with HSPC in 86% of cases. Loss
of PTEN expression was associated with shorter median overall survival (14 vs 21 mo;
hazard ratio [HR]: 1.75; 95% conﬁdence interval [CI], 1.19–2.55; p = 0.004) and shorter
median duration of abiraterone treatment (24 vs 28 wk; HR: 1.6; 95% CI, 1.12–2.28;
p = 0.009). PTEN protein loss, high lactate dehydrogenase, and the presence of visceral
metastases were identiﬁed as independent prognostic factors in multivariate analysis.
Conclusions: Our results indicate that loss of PTEN expressionwas associatedwithworse
survival and shorter time on abiraterone treatment. Further studies in larger and
prospective cohorts are warranted.
Patient summary: PTEN is a protein often lost in prostate cancer cells. In this study we
evaluated if prostate cancers that lack this protein respond differently to treatment with
abiraterone acetate. We demonstrated that the survival of patients with loss of PTEN is
shorter than patients with normal PTEN expression.
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Prostate cancer (PCa) is the most commonmalignant tumor
in men and carries significant morbidity and mortality
[1]. Substantial improvements have been made in the
molecular characterization of this disease, but these have
not yet been translated into relevant stratification in clinical
practice [2].
Loss of the tumor suppressor phosphate and tensin
homolog (PTEN) is one of the most common molecular
aberrations in PCa and has been correlated with a poor
prognosis [3–10]. As a lipid phosphatase and negative
regulator of the PI3K/AKT/mTOR pathway, PTEN controls a
number of cellular processes including survival, prolifera-
tion, metabolism, migration, and cellular architecture
[11]. Preclinical data have proposed a role for PTEN loss
and activation of the PI3K/AKT pathway in regulating
androgen receptor (AR) transcriptional output and in
driving resistance [5,12–14].
PTEN has attracted great interest as a biomarker in PCa.
Initial assessments of PTEN loss mostly focused on genomic
deletions of the PTEN locus identified by fluorescence in
situ hybridization (FISH) [7,15]. However, multiple mecha-
nisms account for loss of PTEN protein expression including
genomic deletion, mutation, microRNA, and promoter
methylation [16], and FISHmay therefore be systematically
underestimating the frequency of loss of PTEN in PCa
[8,15–18].
Reliable analysis of PTEN status by immunohistochemis-
try (IHC) in routinely processed clinical formalin-fixed and
paraffin-embedded (FFPE) pathology specimens has been
established [19], and good concordance has been demon-
strated between FISH detection of PTEN deletions and
the overall cellular PTEN protein expression by IHC [8,15,
18,20]. Importantly, assessment of PTEN protein expression
by IHC offers the advantage of detecting loss of PTEN by
mechanisms other than genomic deletion [8,15].
In this retrospective study we investigated PTEN
protein expression in hormone-naive prostate cancer and
castration-resistant prostate cancer (CRPC) tissue and its
association with clinical outcome in metastatic CRPC
patients treated with the CYP17 inhibitor abiraterone
acetate (abiraterone).
2. Patients and methods
2.1. Patient cohort
Potentially eligible cases were identiﬁed from a population of men with
CRPC treated at the Royal Marsden NHS Foundation Trust between
January 2006 and December 2013. Patients were included in this study if
they had received abiraterone plus prednisolone treatment following
docetaxel for metastatic CRPC and had available parafﬁn tissue blocks
frommetastatic sites or primary tumors for PTEN IHC. Exclusion criteria
were previous treatment with a PI3K/AKT inhibitor or enzalutamide.
Patients with histologic features supporting a diagnosis of pure
neuroendocrine or small cell cancer were not included. All patients gave
their written informed consent and were enrolled in institutional
protocols approved by the Royal Marsden NHS Foundation Trust Hospital
(London, UK) ethics review committee (reference no. 04/Q0801/60).Demographics and clinical data were retrospectively collected from the
hospital electronic patient record system.
2.2. Tissue samples
PCa tissue was obtained from prostate needle biopsies, transurethral
resections of the prostate, prostatectomies or PCa metastases within bone
(bone marrow trephine), lymph node, or viscera (needle biopsies)
(Supplementary Table 1). A subset of patients had matched therapy-naive
hormone-sensitiveprimary tissueandCRPCfresh tumorsamplesavailable.
All tissue blockswere resectioned and reviewed by a pathologist (D.N.R. or
K.T.) for conﬁrmation of the adequacy of the material (50 viable cells).
2.3. PTEN immunohistochemistry
PTEN protein expression was determined by IHC on 4-mM-thick FFPE
sections as previously described [15,21]. Brieﬂy, PTEN immunoreactivity
was investigated using a rabbit monoclonal anti-PTEN antibody 138G6
(catalog no. 9559; Cell Signaling Technology, Inc, Danvers, MA, USA) [19]
detected using the Vectastain Elite ABC kit (catalog no. PK-6101; Vector
Laboratories, Burlingame, CA, USA). Nuclear and cytoplasmic staining
intensity were semiquantitatively assessed using the H-score formula:
3 times percentage of strongly staining cells and 2 times percentage of
moderately staining cells and percentage of weakly staining cells, giving a
rangeof0–300[22]. PTEN-positive controls includednormalprostate tissue
and 22RV1 xenograft tissue, and PTEN-loss controls included PC3 (PCa cell
line-PTEN null) xenografts. Endothelial cells and stroma were used as
internal positive controls for PTEN. Because there is no validated standard
deﬁnition for PTENpositivity or loss on the basis of our extensive literature
review and personal discussions, we devised a binary classiﬁcation system
in which cases were considered PTEN negative if they either showed a
complete absence of PTEN staining or weak intensity staining compared
with internal control innomore than10%of cancer cells (H-score10). The
evaluation of all IHC sections was done by a pathologist (D.N.R.) blinded to
the patients’ clinical characteristics and outcome data. The PTEN IHC assay
and binary classiﬁcation systemwas validated in a series of PCa specimens
for which we had available PTEN genomic status by FISH (n = 103).
A fraction of tumors showed prominent intratumor heterogeneity for
PTEN expression with clearly distinct PTEN-positive and PTEN-negative
areas, suggesting two clear populations of tumor cells in which one
population had PTEN loss and the other did not. For the purpose of data
analysis, a case was considered PTEN negative if any tumor area showed
a complete absence of PTEN staining. For the purpose of survival analysis
when a change in PTEN status was observed between patient-matched
hormone-sensitive prostate cancer (HSPC) and CRPC samples, caseswere
classiﬁed accordingly to the PTEN status in the CRPC sample.
2.4. Fluorescence in situ hybridization
PTEN FISH was performed as described previously [7,21,23] on 4-mM
FFPE tissue slices adjacent to hematoxylin and eosin sections that were
conﬁrmed to contain a minimum of 50 intact cells. All the tissues were
then scanned using an Ariol SL-50 scanner (Applied Imaging); all areas of
tumorwere scored for PTEN loss by FISH status by an operator blinded to
the IHC results. Heterozygous deletionswere recordedwith>30% of cells
containing one signal for the locus probe and two or more signals for the
chromosome 10 control probe. Homozygous deletions were recorded by
the loss of both copies of PTEN locus probe and the presence of two or
more signals for chromosome 10 control probe in>30% of cells as cut-off.
2.5. Statistical analyses
Biochemical response to abirateronewas deﬁned per the Prostate Cancer
Working Group Criteria 2 as a 50% decline in prostate-speciﬁc antigen
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measured from the ﬁrst date of abiraterone treatment to the date of last
contact or to the date of death from any cause. The Kaplan-Meier product-
limit method was used to estimate the duration of abiraterone treatment
and overall survival. Independent sample t tests and Pearson chi-square
were used to study the association of PTEN loss with continuous and
categorical variables, respectively. All tests were two sided, and a p value
0.05was considered statistically signiﬁcant. Univariate andmultivariate
analyses of the independent factors for overall survival were performed
using the Cox regression model with a 95% conﬁdence interval (CI). High/
low values for accepted normal ranges were used for laboratory
parameters [25]. PSA was highly skewed, and the logarithm function
was used to transform this variable. Twenty-seven patients had at least
one missing baseline variable. Descriptive statistics and survival analyses
were performed using IBM SPSS Statistics v.22.
3. Results
3.1. Validation of immunohistochemical cut-off
Because no validated standard definition for PTEN positivity
or loss by IHC exists, we first determined if our PTEN IHC
assay and binary classification system was sensitive for
detecting PTEN loss in clinical PCa specimens.We evaluated
PTEN protein by IHC in a series of PCa specimens for which
we had available PTEN genomic status by FISH (n = 103). In
patients with no deletion of PTEN, a variable degree of
cytoplasmic and nuclear PTEN protein immunostaining was
evident (Fig. 1), whereas patients with homozygous loss of
both PTEN alleles had loss of PTEN protein by IHC with a
median cytoplasmic H-score of 0 (range: 0–10) (Fig. 1).
According to our classification system, 100% of patients
with homozygous loss were classified as PTEN negative.
PTEN expression in patients with heterozygous loss was
low/absent with a median cytoplasmic PTEN H-score of 0
(range: 0–80) (Fig. 1), confirming previous observations
that patients with heterozygous loss commonly have loss of
PTEN expression by IHC [8,15]. Taken together, these results
confirmed our PTEN IHC was sensitive for the detection of
genomic PTEN loss and the validity of our cut-off to classify
PTEN status.[(Fig._1)TD$FIG]0
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Fig. 1 – Cytoplasmic (right) and nuclear (left) PTEN H-score in specimens with
(FISH) (no deletion); heterozygous somatic PTEN loss by FISH (heterozygous lo
loss). Staining intensity in prostate cancer cells was scored 0–3 (negative; weak
of cancer cells staining positively to generate an H-score (0–300). PTEN protein
FISH = fluorescent in situ hybridization.3.2. Metastatic prostate cancer patients commonly have loss of
PTEN protein expression
A total of 144 patients were identified who had received
treatment with abiraterone in the post-docetaxel setting
and had tissue available for PTEN analysis. One single tissue
sample was available for 95 patients; 42 patients had two
tissue samples collected at different time points, and 7 had
three tissue samples available for analysis. PTEN protein
was scored by IHC in 200 tissue samples from 144 patients
(Supplementary Table 1). PTEN loss occurred in 38% (54 of
140) of the primary tumor samples and 50% (30 of 60) of the
metastatic CRPC samples. There was no significant associa-
tion between PTEN loss and specimen type (primary vs
metastatic; p = 0.1 by Pearson chi-square test). Of note,
however, was that the rate of PTEN loss in liver metastases
was higher than that in other sites (70% [7 of 10]). Nine of
the 140 primary tumor samples (6%) (eight prostate needle
biopsies, one radical prostatectomy) showed prominent
intratumor heterogeneity for PTEN expression, with distinct
areas positive for PTEN, whereas other areas showed
absence of PTEN staining (Fig. 2).
Overall, PTEN loss was demonstrated in 40% of patients
(57 of 144). Forty-nine patients had two samples collected
at different times evaluated for PTEN expression. The
median interval between the first and second sample
collection was 4.7 yr (interquartile range [IQR]: 2.2–8.9).
Intrapatient concordance was demonstrated in 90% of the
cases (44 of 49). According to our classification, a change in
PTEN status was only observed in 5 of 49 patients. The PTEN
status by IHC in primary prostate tissue and distant
metastases is presented in Supplementary Table 2.
3.3. PTEN status does not usually change with the development
of castration-resistant prostate cancer
We next examined PTEN status in matched same-patient
HSPC and CRPC tissue to evaluate if the frequency of PTEN
loss changed with disease progression. Matched HSPC and
CRPC tissue samples were available for 41 patients. Staining0
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no somatic cell deletion of PTEN by fluorescent in situ hybridization
ss); and homozygous (biallelic) somatic PTEN loss by FISH (homozygous
; moderate; intense), and this value was multiplied by the percentage
loss was defined as an H-score =10 (red line).
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Fig. 2 – Micrographs show PTEN expression by diaminobenzidine immunohistochemistry method in six samples. (A) Column A displays three
micrographs of primary prostate adenocarcinoma. (A1) Needle biopsy with moderate nuclear and cytoplasmic PTEN protein expression (T100
magnification). (A2) Prostatectomy specimen with extensive PTEN protein negative adenocarcinoma infiltration. In the upper right-hand corner,
cytoplasmic PTEN protein–positive benign glands are adjacent to invasive carcinoma (T50 magnification). (A3) Prostatectomy specimen showing
heterogeneous PTEN protein expression (T50 magnification). Two inserted photographs at T200 magnification demonstrate cytoplasmic positivity
(upper right: short dashes square) and negativity (bottom left: long dashes square). Nuclear staining was predominantly negative in both areas.
(B) Column B shows three matched metastatic castration-resistant prostate cancer samples acquired at a later time point from the same patients as
the respective diagnostic samples in column A. (B1, B2) PTEN negativity has been verified in bone marrow and liver metastases, respectively (T200
magnification). (B3) PTEN nuclear and cytoplasmic positivity is demonstrated in tumor nests of a lymph node biopsy (T200 magnification).
CRPC = castration-resistant prostate cancer.
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(18 of 41) and 57% (22 of 41) of the HSPC and CRPC tumor
specimens, respectively. Overall concordant PTEN status
was evident between matched HSPC and CRPC tissuesamples in 86% of cases (32 of 37 patients); a change in
classification from PTEN positive to PTEN negative was
reported in three patients (7%), and conversely from PTEN
negative to PTEN positive in two patients (5%). Intratumor
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Overall Survival (95% CI)
PTEN negative 14 mo (10–18)
PTEN positive 21 mo (15–27)
HR:1.75; 95% CI, 1.19–2.55)
p = 0.004
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41 HSPC and in 1 CRPC; 3 of the 5 heterogeneous HSPC
samples demonstrated eventual complete loss of PTEN
expression in the CRPC sample; 1 retained PTEN expression;
and 1 showed heterogeneity also in the CRPC sample.
3.4. Loss of PTEN expression associates with worse clinical
outcome
At the commencement of abiraterone treatment, the
median age was 68 yr (IQR: 63–73), and all patients hadTable 1 – Demographic and clinical characteristics of patients at
the time of abiraterone initiation
Overall
n = 144
PTEN
negative
n = 57
PTEN
positive
n = 87
p value
Age, yr
Median 68 66 69 >0.9a
IQR 63–73 62–72 65–73
Gleason score at diagnosis, n (%)
6 15 (10) 7 (12) 8 (10) 0.06b
7 33 (23) 19 (33) 14 (16)
8–10 71 (49) 23 (41) 48 (55)
NA 25 (17) 8 (14) 17 (19)
Sites of metastases, n (%)
Bone 128 (88) 52 (91) 76 (87) 0.7c
Nodal 75 (51) 28 (48) 47 (54) 0.7c
Visceral 25 (17) 14 (24) 11 (12) 0.03c
ECOG PS, n (%)
0 35 (24) 13 (23) 22 (25)
1 86 (60) 35 (61) 51 (59) 0.4b
2 7 (5) 4 (7) 3 (3)
NA 16 (11) 5 (9) 11 (13)
PSA, mg/l
Median 213 155 237 0.5a
IQR 60–681 56–660 67–762
Hemoglobin, g/dl
Median 11.6 11.8 11.5 0.9a
IQR 10.5–12.7 10.4–12.6 10.5–12.8
NA 17 4 13
Alkaline phosphatase, IU/l
Median 131 155 124 0.2a
IQR 69–253 77–251 69–272
NA 13 4 9
Lactate dehydrogenase, IU/l
Median 188 216 181 >0.9a
IQR 154–246 154–343 155–226
NA 22 7 15
Albumin, g/l
Median 35 35 36 0.4a
IQR 33–38 32–38 33–38
NA 14 4 10
Previous treatments for CRPC, n (%)
Docetaxel 144 (100) 57 (100) 87 (100)
Cabazitaxel 11 (8) 4 (7) 7 (8) 0.8c
Other agents 19 (21) 8 (14) 11 (12) 0.8c
Systemic therapy after abiraterone, n (%)
Cabazitaxel 43 (30 17 (30) 26 (30) >0.9c
Other agents 42 (29) 24 (42) 31 (36) 0.3c
CRPC = castration-resistant prostate cancer; ECOG PS = Eastern Cooperative
Oncology Group performance status; IQR = interquartile range; NA = not
available; PSA = prostate-speciﬁc antigen.
The p values refer to signiﬁcance of difference compared with PTEN positive.
a Mann-Whitney test.
b Chi-square test for trend.
c Pearson chi-square test.
12223143257negativePTEN
026713305887positivePTEN
No. at risk Time to death, mo
Fig. 3 – Kaplan-Meier survival curves from initiation of abiraterone
treatment according to PTEN expression status demonstrating a
significantly shorter overall survival for patients with PTEN protein loss.
CI = confidence interval; HR = hazard ratio.radiologically detectable metastatic disease. The most
common sites of metastases were bone (88%), lymph nodes
(51%), and visceral (17%). Eastern Cooperative Oncology
Group performance status was 0 or 1 in 121 patients (84%).
Fifty-four patients (38%) received abiraterone within
a clinical trial. The median follow-up was 16 mo (range:
1–90 mo). Table 1 details the demographic and clinical
characteristics at the time of abiraterone initiation. Of note,
a higher percentage of patients in the PTEN-negative group
had visceral metastases at the time of abiraterone initiation
(24% vs 12%; p = 0.03) (Table 1). There were no other
significant differences in baseline characteristics between
the PTEN-positive and PTEN-negative groups. After pro-
gression on abiraterone, 30% of patients in each group
received cabazitaxel treatment.
In univariate analyses, loss of PTEN expression was
significantly associated with a shorter median overall
survival (14 vs 21 mo; hazard ratio [HR]: 1.75; 95% CI,
1.19–2.55; p = 0.004; Fig. 3). Loss of PTENprotein expression,Table 2 – Multivariate Cox regression analysis for overall survival
HR 95% CI p value
PTEN status, negative vs positive 1.56 1.02–2.40 0.04
Low albumin, yes vs no 0.96 0.43–2.11 >0.9
High ALP, yes vs no 1.39 0.83–2.30 0.2
Low hemoglobin, yes vs no 1.81 0.94–3.47 0.07
High LDH, yes vs no 1.59 1.00–2.52 0.048
Visceral metastases, yes vs no 1.97 1.09–3.55 0.02
logPSA* 1.09 0.79–1.50 0.6
Age* 1.02 0.98–1.06 0.3
ECOG PS 2, yes vs no 0.97 0.33–2.85 >0.9
Previous cabazitaxel, yes vs no 1.96 0.72–5.30 0.2
ALP = alkaline phosphatase; CI = conﬁdence interval; ECOG PS = Eastern
Cooperative Oncology Group performance status; HR = hazard ratio;
LDH = lactate dehydrogenase; PSA = prostate-speciﬁc antigen.
Values in bold are statistically signiﬁcant at a = 0.05. Hospital high/low
values for accepted normal ranges were used for laboratory parameters.
* Continuous variables.
Table 3 – Abiraterone activity according to PTEN expression
PTEN negative
n = 57
PTEN positive
n = 87
p value
PSA decline
50%, n (%) 18/56* (32) 38/87 (43) 0.2
30%, n (%) 24/56* (43) 48/87 (55) 0.2
Duration of
abiraterone
treatment, wk
24 28 0.009
PSA = prostate-speciﬁc antigen; PTEN = phosphatase and tensin homolog.
Values in bold are statistically signiﬁcant at a = 0.05.
* Data for one patient are missing.
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visceral metastases were identified as independent factors
for overall survival in multivariate Cox regression analysis
(Table 2).
Confirmed PSA declines of at least 50% in the absence of
radiographic progression were observed in 18 of the
56 patients with loss of PTEN (32%) and in 38 of the
87 patients (43%) (p = 0.2). The median duration of abirater-
one treatment for patients in the PTEN-negative group was
shorter than that for the PTEN-positive group (24 vs 28 wk;
HR: 1.6; 95% CI, 1.12–2.28; p = 0.009) (Table 3).
4. Discussion
Loss of PTEN is a common molecular aberration in PCa and
believed to be critically important in regulating AR signaling
output [5,13,14]. Preclinical studies have demonstrated the
existence of reciprocal feedback regulation between the AR
and PI3K/AKT pathway in PTEN-deficient models that
confers survival advantage and resistance to single pathway
inhibition [5,26].
In this retrospective study we investigated PTEN
expression in metastatic CRPC patients who had received
treatment with abiraterone post-docetaxel and its asso-
ciation with clinical outcome. We used a specific antibody
directed against the extreme carboxy-terminal sequence
of human PTEN protein [3,8,15,19] and used a stringent
cut-off to define PTEN negativity that was validated in
cases with biallelic genomic losses by FISH. Loss of PTEN
expression occurred in 40% of patients and was associated
with a shorter duration of abiraterone treatment and
poorer overall survival. The study was retrospective in
design with the inherent biases and confounders of all
retrospective studies including the lack of data on
comorbidities and comprehensive data on tumor volume
and radiologic responses. Nonetheless, our data indicate
that patients with loss of PTEN may have a worse clinical
outcome when treated with abiraterone. These findings
require replication in an independent data set but support
the evaluation of PTEN as a biomarker in trials with
combinations of novel AR-targeting drugs (abiraterone or
enzalutamide) and PI3K/AKT inhibitors for patients with
CRPC.
Inherent in PCa studies is intratumoral heterogeneity
that can lead to misclassification and confound the
association with outcomes. In keeping with previousstudies, heterogeneity of PTEN expression was observed
in 6% of primary tumors, mostly obtained in our cohort by
needle biopsies [3,8]. Nevertheless, with our binary
classification system, we observed good concordance
(90%) between same-patient samples collected at multiple
time points and in matched HSPC and CRPC tissue (86%).
These findings require further validation in large indepen-
dent cohorts, with possible interrogation of heterogeneity
in primary and especially in metastatic disease.
5. Conclusions
To the best of our knowledge, this is the first report of an
association between PTEN protein expression status and
clinical outcome in metastatic CRPC patients. PTEN loss has
been shown to be frequently, but not always, associated
with the presence of transmembrane protease, serine 2-v-
ets avian erythroblastosis virus E26 oncogene homolog
(TMPRSS2-ERG) rearrangements [9,27,28]. Discordant
results have been published concerning the prognostic
effect of loss of PTEN in the contest of ERG fusion [7,9,29,30].
PTEN loss is also accompanied by frequent alterations in the
PI3K/AKT signaling pathway network involving inositol
polyphophate-4 phosphatase, type II, 105kDa (INPP4B); PH
domain and leucine rich repeat protein phosphatase 1
(PHLPP); and phosphoinositide-3-kinase, regulatory sub-
unit 1 (alpha) (PIK3R1) [27]. Characterization of PTEN, along
with ERG and possibly other key proteins implicated in this
pathway, as part of larger studies with well-powered
analyses are now warranted to better define the impact of
PTEN loss on response to novel AR-targeting agents
including studies of their interaction with ETS gene
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